New Mexico Prescription Monitoring Program Data Report

Similar documents
Drug Overdose in New Mexico

Trends in Indicators of Opioid and Methamphetamine Use in New Mexico and Bernalillo County,

2015 HOUSING CREDIT INCOME LIMITS AND MAXIMUM RENTS

Cancer in New Mexico 2014

Cancer in New Mexico 2017

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

Table of Contents. 2 P age. Susan G. Komen

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

Dee Johnson Clean Indoor Air Act

2003 NEW MEXICO SOCIAL INDICATOR REPORT

NEW MEXICO INFLUENZA SURVEILLANCE UPDATE Influenza Season

The Role of Substance Use Epidemiology, New Mexico Department of Health

New Mexico State Epidemiology Profile Strategic Prevention Framework - State Incentive Grant (SPF-SIG)

Opportunities for Cancer Control An overview of screen-detectable and tobacco-related cancer in New Mexico

2013 Rankings New Mexico

Burden of Substance Use in New Mexico. Michael Landen, MD, MPH State Epidemiologist New Mexico Department of Health April 12, 2018

2012 Rankings New Mexico

New Mexico Substance Abuse Epidemiology Profile

Sierra County Community Health Profile

Luna County Community Health Profile

Los Alamos County Community Health Profile

Mora County Community Health Profile

New Mexico Substance Abuse Epidemiology Profile

Taos County Community Health Profile

Eddy County Community Health Profile

NM Department of Homeland Security and Emergency Management

Putnam County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome Among Adults and Adolescents in New Mexico 2014

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Bernalillo County Community Profile

Barbour County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report Barbour County

Mingo County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Kanawha County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Pocahontas County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome Among Adults and Adolescents in New Mexico 2016

1996 HOSPITAL INPATIENT DISCHARGE DATA (HIDD)

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)

Opioid Use and Other Trends

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)

The Epidemiology of Opioid Abuse. Thomas Dobbs, MD, MPH Mississippi State Department of Health

The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017

Tuberculosis Mortality Risk Factors in New Mexico. NM Dept of Health/UNM Brown University

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

New Mexico High Intensity Drug Trafficking Area

Wherever the art of medicine is practiced there is also a love of humanity. Hippocrates. New Mexico Office of the Medical Investigator

Results from the 2012 New Mexico Community Survey

An Integrated Healthcare System s Approach to Chronic Pain

New Mexico Department of Health Influenza & Respiratory Disease Report,

Pennsylvania Prescription Drug Monitoring Program Trends,

PRESCRIPTION DRUG MONITORING PROGRAM

The Morbidity and Mortality of Kansas Drug Epidemic

2 nd Bernalillo County Opioid Abuse Accountability Summit Data Series January 8, 2015

2014 Hospital Inpatient Discharge Data Annual Report

ALAMO AND TO HAJIILEE NAVAJO HEALING TO WELLNESS COURT TRIBAL WELLNESS COURTS ENHANCEMENT TRAINING SEPTEMBER 8, 2014

Addressing the Opioid Epidemic in Tennessee

Strategic Prevention Framework for Prescription Drugs

Prescription Opioid Overdose in Oregon: A public health perspective

Blue Cross of Idaho Addresses State s Opioid Issue

Opioid Management of Chronic (Non- Cancer) Pain

CDC Guideline for Prescribing Opioids for Chronic Pain

New Mexico Waterborne Disease Surveillance Project Annual Report 2005

PRESCRIPTION DRUG MONITORING PROGRAM ST. CHARLES COUNTY Q1 2018

Kentucky All Schedule Prescription Electronic Reporting (KASPER)

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities

The STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018

Arkansas Prescription Monitoring Program

Prescription Monitoring Program Center of Excellence at Brandeis. Drug-Related Deaths in Virginia: Medical Examiner Use of PMP Data

2010 NEW MEXICO EMERGENCY DEPARTMENT DATA REPORT

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

Controlled Substance Prescribing Trends and Odds of Drug Overdose Death

Medicare Advantage Outreach and Education Bulletin

CDC s Efforts to End the Opioid Epidemic

The Wisconsin Prescription Drug Monitoring Program

Results from the 2014 New Mexico Community Survey

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

New Mexico Department of Health Influenza & Respiratory Disease Report

Opioids drive continued increase in drug overdose deaths

NEW MEXICO BORDER HEALTH REPORT

OPIOID CRISIS: A PERSPECTIVE. Karl J. Haake, MD

ARKANSAS DEPARTMENT OF HEALTH

Medicare Part D Opioid Policies for 2019 Information for Patients

Figure 1. National Drug Overdose Deaths Number Among All Ages, by Gender,

Opioid Prescribing Improvement Program

The State of Health in New Mexico New Mexico Department of Health

Opioid Overdose in Oregon Report to the Legislature

SEX CRIMES IN NEW MEXICO X:

Section I. Short-acting opioid Prior Authorization Criteria

Opioid Review and MAT Clinic CDC Guidelines

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

Prescription Drug Abuse Task Force Rx Report Card

New Guidelines for Prescribing Opioids

Transcription:

New Mexico Prescription Monitoring Program Data Report 26 213

Table of Contents Introduction... 2 Methods... 3 Results... 4 Demographics... 5 Opioids... 5 Benzodiazepines... 6 Trends over time... 7 Opioids... 7 Benzodiazepines... 8 Geography... 9 Opioids... 9 Benzodiazepines... 11 Prescribing patterns... 13 High dose... 15 Opioids plus benzodiazepines... 15 Opioids, Benzodiazepines and Carisoprodol... 16 Multiple practitioners... 17 Summary... 18 1

Introduction Drug overdose death has become the leading cause of injury death in New Mexico and nationally over the past decade (New Mexico Substance Abuse Epidemiological Profile, 213). New Mexico had the second highest drug overdose death rate, after West Virginia, in 21 (CDC Wonder). In the period from 28 212, there were an average of 483 drug overdose deaths in New Mexico each year, more than three times as many as there were in 199 1994. Overdose deaths involving prescription drugs averaged 325 per year in 28 212 in New Mexico, compared to an average of 211 deaths per year involving illicit drugs (these two categories are not mutually exclusive). The number of overdose deaths involving prescription drugs exceeded the number involving illicit drugs in 26, and now outnumber illicit drug overdose deaths by 6% (Figure 1). 3 Figure 1: Overdose death rates involving prescription and illicit drugs, New Mexico 199 212 Deaths per 1, population 25 2 15 1 5 Total Prescription Illicit 199 1991 1992 1993 1994 1995 1996 1997 1998 1999 2 21 22 23 24 25 26 27 28 29 21 211 212 Categories are not mutually exclusive Rates are age adjusted to the US 2 standard population Source: Office of the Medical Investigator; UNM/GPS population estimates In response to the increase in prescription drug overdose, the New Mexico Prescription Monitoring Program (PMP) was established in 25. The PMP is operated by the New Mexico Board of Pharmacy 2

under the board s authority to regulate pharmacies and has been in place since July 25. All controlled substance prescriptions filled by pharmacies are required to be reported to the PMP within seven days. The information collected by the PMP is similar to the information on a prescription label, and identify the prescriber, the patient, the pharmacy, the drug and details of the prescription such as quantity and number of days of supply. More than 3 million prescriptions for controlled substances are reported to the NM PMP each year. Controlled substances are a special class of prescription drugs that are considered substantially more dangerous than other prescription drugs. Controlled substances were involved in 88% of the drug overdose deaths that involved prescription drugs in 29 213 in New Mexico. Methods PMP data for 26 213 were analyzed for this report. The data represent prescriptions filled (including refills) by patients in that period. Prescriptions written by veterinarians are excluded. Population estimates used for rates are from the Geospatial and Population Studies (GPS) program at the University of New Mexico. There are a number of factors that should be taken into consideration when reviewing information from the PMP: Federal pharmacies (Military, Veterans Administration and Indian Health Service) cannot be required to report to the state system. However, some have begun reporting on a voluntary basis in the last year or two. In some counties Federal pharmacies account for a significant fraction of the prescriptions dispensed, and their addition may impact the apparent trends over time. Age and gender are captured by the PMP, but race/ethnicity is not. PMP data does not contain information about the diagnosis underlying the prescription. Prescriptions for cancer or hospice care cannot be excluded or analyzed separately. The PMP tracks prescriptions filled, not consumed. For example, a patient may fill a 3 day prescription for an opioid pain reliever but only use 3 days of medication. The main classes of drugs analyzed in this report are: Opioids, which are powerful pain relievers. Opioids have a significant risk of causing overdose death. Examples are morphine, oxycodone and hydrocodone. Because opioids vary widely in strength, a factor is applied to each opioid prescription to compute the morphine milligram equivalent (MME) quantity of that prescription. This allows computing a measure of the total amount of opioids dispensed taking into account the different strengths of the drugs. Benzodiazepines, which are sedative/hypnotic drugs. Benzodiazepines are frequently involved in overdose deaths, but they are very rarely the only drug involved. In these data, the 3

benzodiazepine like drugs, which are insomnia drugs like Ambien, are included in the benzodiazepine category. Like opioids, benzodiazepines vary in strength, so a factor is applied to each prescription to compute the valium milligram equivalent (VME). Results Opioids are by far the most commonly prescribed controlled substances. In 213 opioids accounted for 54% of all controlled substance prescriptions filled, followed by benzodiazepines at 29% (Figure 2). The only muscle relaxant on the controlled substance list is Carisoprodol (Soma ). Figure 2: Prescriptions Reported to the NM PMP, 213 Opioids Benzodiazepines Stimulants Barbiturates Muscle Relaxants Other Source: NM PMP 5, 1,, 1,5, 2,, Number of Prescriptions filled Note: These are number of prescriptions filled, not numbers of patients. Patients may receive multiple prescriptions in a year. 4

Demographics Opioids Figure 3a: Patients Filling Opioid Prescriptions per 1, Population, NM 213 Patients per 1, population 5 4 3 2 1 4 5 14 15 24 25 34 35 44 45 54 55 64 65 74 75 84 85+ Age group Source: NM PMP; UNM/GPS population estimates Male Female New Mexicans were more likely to fill opioid prescriptions as they aged (Figure 3a). Women were slightly more likely to fill opioid prescriptions than men. However, the amount of MME consumed is more likely to increase a person s risk of drug overdose and men fill prescriptions with higher MME than women, especially between 25 74 years of age (Figure 3b). This suggests that, although women filled more prescriptions, men filled stronger prescriptions. Middle aged patients, especially ages 55 64, are more likely to be filling high MME prescriptions (Figure 3b). Figure 3b: Opioid MME per Patient, NM 213 MME per patient 7, 6, 5, 4, 3, 2, 1, 4 5 14 15 24 25 34 35 44 45 54 55 64 65 74 75 84 85+ Age group Male Female Source: NM PMP 5

Benzodiazepines Figure 4a: Patients filling Benzodiazepine Prescriptions per 1, Population, NM 213 Patients per 1, population 3 25 2 15 1 5 4 5 14 15 24 25 34 35 44 45 54 55 64 65 74 75 84 85+ Age group Source: NM PMP; UNM/GPS population estimates Male Female Older New Mexicans are more likely to fill benzodiazepine prescriptions then younger New Mexicans (Figure 4a). Women in all age groups are more likely to fill benzodiazepine prescriptions. Women in New Mexico are more likely to have a personal physician than men in New Mexico (NM Behavioral Risk Factor Surveillance System) and this may partially explain why women are more likely to fill prescriptions for opioids or benzodiazepines than men. VME per patient peaks at ages 45 54 years and men under the age of 45 are more likely to be receiving stronger benzodiazepine prescriptions than women (Figure 4b). Figure 4b: Benzodiazepine VME per patient, NM 213 3,5 3, 2,5 2, 1,5 1, 5 4 5 14 15 24 25 34 35 44 45 54 55 64 65 74 75 84 85+ Age group Source: NM PMP VME per patient Male Female 6

Trends over time Trends in filled prescriptions are described in this report using two methods. The first graph shows the number of patients filling prescriptions per 1, population in each year. The second graph for each prescription category is prescription strength per patient, measured as the total amount of prescription filled in a year, over time. Opioids Patients per 1, population 3 25 2 15 1 5 Figure 6a: Patients Filling Opioid Prescriptions per 1, Population, NM 26 213 26 27 28 29 21 211 212 213 Source: NM PMP; UNM/GPS population The number of patients filling opioid prescriptions per population increased 16% in the 26 213 time period (Figure 6a). The annual amount of opioid per prescription increased 44% between 26 and 21. However, the amount of opioid per patient decreased 19% after 21 (Figure 6b). This suggests that prescribing practices are changing over time, reducing the amount of opioids prescribed to patients. Figure 6b: Opioid MME per patient, NM 26 213 MME per patient 5, 4,5 4, 3,5 3, 2,5 2, 1,5 1, 5 26 27 28 29 21 211 212 213 Source: NM PMP; UNM/GPS population 7

Benzodiazepines Patients per 1, population 12 1 8 6 4 2 Figure 7a: Patients Filling Benzodiazepine Prescriptions per 1, population, NM 26 213 26 27 28 29 21 211 212 213 Source: NM PMP; UNM/GPS population The rate of patients filling benzodiazepine prescriptions remained stable over the time period assessed, increasing by 13% (Figure 7a). Annual VME per patient increased from 26 through 213 (27% increase) but may have plateaued since 21 (Figure 7b). Although benzodiazepines are commonly abused, their use alone does not pose as large of a risk for overdose death as opioids. However, in combination with opioids or alcohol, benzodiazepines can be very dangerous. 3, Figure 7b: Benzodiazepine VME per patient, NM 26 213 2,5 VME per patient 2, 1,5 1, 5 26 27 28 29 21 211 212 213 Source: NM PMP; UNM/GPS population 8

Geography Annual prescription strength by county is presented by both in descending order as well as a map to assess geographic disparities. Opioids Sierra Rio Arriba Harding* Grant Hidalgo* Luna Taos Lincoln Torrance Eddy Socorro Valencia De Baca* Bernalillo Sandoval Santa Fe San Miguel New Mexico Mora* Catron* Chaves Colfax Quay Los Alamos Otero Guadalupe* Lea Roosevelt Dona Ana Curry San Juan Cibola McKinley Union* Total MME of Opioids Dispensed per person by County, NM 213 5 1, 1,5 2, Total morphine milligram equivalents (MME) per person * County population under 5, Source: NM Prescription Monitioring Program; UNM/GPS population Sierra County has the highest MME per person in the state. Rio Arriba County, which has the highest drug overdose mortality rate in the state ranks second (Figures 9 &1). 9

Figure 1: Opioid morphine milligram equivalents per patient by county, NM 213 Source: NM Prescription Monitoring Program 1

Benzodiazepines Figure 11: Benzodiazepine VME per person by county, NM 213 Sierra De Baca* Harding* San Miguel Mora* Lincoln Grant Rio Arriba Eddy Colfax Los Alamos Guadalupe* Quay Santa Fe Luna Socorro Hidalgo* Taos Chaves New Mexico Bernalillo Valencia Torrance Sandoval Otero Lea Dona Ana Roosevelt Curry San Juan Union* Cibola Catron* McKinley 2 4 6 Valium milligram equivalents (VME) per person * County population under 5, Source: NM Prescription Monitioring Program; UNM/GPS population Sierra County also has the highest VME per person in the state. McKinley County has the lowest VME per person (Figure 11 & 12). The Southwest portion of the state shows a pattern of strong prescriptions per patient for both opioids and benzodiazepines. 11

Figure 12: Benzodiazepine valium milligram equivalents per person by county, NM 213 Source: NM Prescription Monitoring Program 12

Prescribing patterns There are several prescribing practices that have been associated with increased risk of overdose and are targeted by prevention efforts. These include chronic use of opioids, high dose opioid prescriptions, and certain drug combinations (opioids plus benzodiazepines; and opioids, benzodiazepines and carisoprodol). Also at high risk for overdose are patients who receive prescriptions from multiple providers or fill prescription at multiple pharmacies in a small period of time ( doctor shopping ). The cut offs for these high risk behaviors are still under development, for the purposes of this report, chronic use of opioids is defined as over 9 day prescriptions and that prescriptions were filled in 9% or more of the months in a year (1.8 months of the year), and high dosage of opioid was defined as 12 MME/day per patient Co prescription of opioids and benzodiazepines (percent of opioid patients receiving any benzodiazepine prescription, and percent of opioid patients receiving a benzodiazepine prescription that was over 9 days) and co prescription of opioids, benzodiazepines and carisoprodol (called the trio here for brevity) were assessed. Prescription of the trio was assessed as percent of opioid patients who received any prescriptions for benzodiazepines and carisoprodol in the same month. Doctor shopping was defined as receiving prescriptions from five or more providers or filling prescriptions from five or more pharmacies. 13

5 45 4 35 3 25 2 15 1 5 Figure 15: Opioid patients by consumption pattern and year, NM 26 213 26 27 28 29 21 211 212 213 Chronic Episodic Short term One prescription One prescription: Only one controlled substance prescription filled in the year Short term: More than one prescription filled, but less than 9 days total time from first to last fill Episodic: 9+ days total, but active prescriptions for less than 9% of total time Chronic: 9+ days total, active prescriptions for 9% or more of total time Source: NM PMP The number of patients categorized as chronic opioid users in New Mexico increased from 12.397 (3.3% of all opioid patients) in 26 to 38,154 (8.1% of all opioid patients) in 213 (Figure 15). In the same time period, the fraction of patients filling one opioid prescription and patients with short term use (> 1 prescription, but < 9 days) fell from 75.2% of all opioid patients to 68.4% of all opioid patients. The fraction of opioid patients with episodic use (9+ days use but prescriptions filled in < 9% of the months) remained relatively stable. 14

High dose percent of opioid patients 16% 14% 12% 1% 8% 6% 4% 2% % Figure 16: Percent of opioid patients with any prescription over 12 MME/day, NM 26 213 Source: NM PMP 26 27 28 29 21 211 212 213 The percent of opioid patients who have filled a high dose of prescription opioids (12 MME/day) declined from 14.1% in 26 to 7.3% in 213 (Figure 16). Opioids plus benzodiazepines Figure 17: Percent of opioid patients also prescribed benzodiazepines, NM 26 213 Percent of opioid patients 18% 16% 14% 12% 1% 8% 6% 4% 2% % 26 27 28 29 21 211 212 213 Source: NM PMP Any Over 9 days There has been a slight increase in the percent of opioid patients filling benzodiazepine prescriptions (Figure 17). In 26, 12.7% of opioid patients filled any benzodiazepine prescription, whereas 14.6% did in 213. The percent of opioid patients receiving over 9 days of benzodiazepines remained fairly steady over the time period, increasing from 3.% to 3.9%. 15

A small percent of opioid patients are filling prescriptions that would be categorized as a trio ; at the peak in 21, slightly less than 1% of opioid patients fit this description. Trio prescriptions increased sharply from 26 to 21 (Figure 18). Their use decreased after 21. Any trio decreased from slightly less than 1% in 21 to.6% in 213. Trio prescriptions over 9 days also increased until 21, and declined afterwards, peaking at approximately.4% of opioid patients. Opioids, Benzodiazepines and Carisoprodol 1.2% Figure 18: Percent of opioid patients with the trio, NM 26 213 1.%.8%.6%.4%.2% Any Over 9 days.% 26 27 28 29 21 211 212 213 The trio is defined as having prescriptions for an opioid, a benzodiazepine and carisoprodol in the same month Source: NM PMP 16

Multiple practitioners 3, Number of patients using multiple practitioners, NM 26 213 Number of patients 25, 2, 15, 1, 5, 26 27 28 29 21 211 212 213 Patients using multiple practitioners are those who received prescriptions from five or more prescribers or filled prescriptions at five or more pharmacies in a year Source: NM PMP The number of patients using five or more prescribers or five or more pharmacies for controlled substances rose in recent years, but overall was relatively stable between 4% and 4.5% of all patients since 28. This practice (sometimes called doctor shopping ) is more common among patients who are using prescription drugs non medically. % of patients Percent of patients using multiple practitioners, NM 26 213 5.% 4.5% 4.% 3.5% 3.% 2.5% 2.% 1.5% 1.%.5%.% 26 27 28 29 21 211 212 213 Patients using multiple practitioners are those who received prescriptions from five or more prescribers or filled prescriptions at five or more pharmacies in a year Source: NM PMP 17

Summary Drug overdose is the leading cause of injury death in New Mexico. The increase in overdose death over the past decade has been driven by an increase in prescription drug overdose death. Opioids are the most common class of controlled substances filled in New Mexico. Opioids and benzodiazepines account for 83% of controlled substance fills. The prevalence of opioid prescriptions rises with age, and women fill more opioid prescriptions than men. The highest doses are in ages 45 64, and men have higher doses than women. The rate of benzodiazepine prescriptions also rises with age and women are also more likely to fill benzodiazepine prescriptions. The number of patients filling opioid prescriptions increased by 16% between 26 and 213. The total amount of opioids per patient decreased by 19% from 21 to 213. The rate of patients filling benzodiazepine prescriptions and the quantity of benzodiazepines per patient have been relatively stable over the period, but the number of benzodiazepine patients per 1, population decreased slightly since 21. The southwestern quarter of New Mexico plus Taos and Rio Arriba counties have the highest rates of opioid morphine milligram equivalents per patient. Eastern and northwestern New Mexico tend to have the lowest rates. The geographic pattern for Benzodiazepines is less concentrated than that for opioids, but some of the same counties in the southwest and north have high rates of both opioid and benzodiazepine prescriptions. The number of patients using controlled substances grew by approximately 2% between 26 and 213. The fraction of all patients who are longer term (9 days or more) increased over the period. The fraction of users who have filled high dose opioid prescriptions in a year declined by almost half from 26 through 213. The fraction of opioid patients who were also prescribed benzodiazepines in the same month peaked in 21 and declined slightly through 213. The fraction of opioid patients who also were prescribed benzodiazepines and carisoprodol in the same month also peaked in 21 and declined sharply to 213. The fraction of all patients who received prescriptions from five or more prescribers or filled prescriptions and five or more pharmacies in one year ranged between 4. and 4.5 percent of all patients from 28 through 213. 18